A Comparison of Adherence and CD4 Cell Count with Respect to Virologic Failure Among HIV-Infected Adults Under Combination Antiretroviral Therapy (cART) at Felege Hiwot Teaching and Specialized Hospital, Bahir Dar, Ethiopia

References

• Lichtfuss GF, Hoy J, Rajasuriar R, Kramski M, Crowe SM, Lewin SR. Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. Biomark Med. 2011;5(2):171–186. doi:10.2217/bmm.11.15
   PubMed Web of Science ®Google Scholar
• Langebeek N, Gisolf EH, Reiss P, et al. Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. BMC Med. 2014;12(1):1–14.
   Web of Science ®Google Scholar
• Sabin CA. Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy? BMC Med. 2013;11(1):1–7. doi:10.1186/1741-7015-11-251
   PubMed Web of Science ®Google Scholar
• Welles S, Jackson J, Yen-Lieberman B, et al. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior Zidovudine therapy. Clin Infect Dis. 1996;174(4):696–703. doi:10.1093/infdis/174.4.696
   Web of Science ®Google Scholar
• Aidala AA, Wilson MG, Shubert V, et al. Housing status, medical care, and health outcomes among people living with HIV/AIDS: a systematic review. Am J Public Health. 2016;106(1):e1–e23. doi:10.2105/AJPH.2015.302905
   PubMed Web of Science ®Google Scholar
• Group SfMoATS. CD4+ count–guided interruption of antiretroviral treatment. N Engl j Med. 2006;2006(355):2283–2296.
   Google Scholar
• Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor–based HIV therapy and virologic outcomesEffect of NNRTI–based HIV therapy adherence on HIV-1 RNA. Ann Intern Med. 2007;146(8):564–573. doi:10.7326/0003-4819-146-8-200704170-00007
   PubMed Web of Science ®Google Scholar
• Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. Aids. 2001;15(16):2109–2117. doi:10.1097/00002030-200111090-00006
   PubMed Web of Science ®Google Scholar
• Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–941. doi:10.1086/507526
   PubMed Web of Science ®Google Scholar
• Bisson GP, Gross R, Bellamy S, et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med. 2008;5(5):e109. doi:10.1371/journal.pmed.0050109
   PubMed Web of Science ®Google Scholar
• Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006;43(1):78–84. doi:10.1097/01.qai.0000225015.43266.46
   PubMed Web of Science ®Google Scholar
• Deribew A, Biadgilign S, Berhanu D, et al. Capacity of health facilities for diagnosis and treatment of HIV/AIDS in Ethiopia. BMC Health Serv Res. 2018;18(1):1–8. doi:10.1186/s12913-018-3347-8
   PubMed Web of Science ®Google Scholar
• Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother. 2004;53(5):696–699. doi:10.1093/jac/dkh162
   PubMed Web of Science ®Google Scholar
• Walsh JC, Pozniak AL, Nelson MR, Mandalia S, Gazzard BG. Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. J Acquir Immune Defic Syndr. 2002;30(3):278–287. doi:10.1097/00126334-200207010-00003
   PubMed Web of Science ®Google Scholar
• Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003;37(8):1112–1118. doi:10.1086/378301
   PubMed Web of Science ®Google Scholar
• Grossberg R, Gross R. Use of pharmacy refill data as a measure of antiretroviral adherence. Curr HIV/AIDS Rep. 2007;4(4):187–191. doi:10.1007/s11904-007-0027-4
   PubMedGoogle Scholar
• Trevethan R. Sensitivity, specificity, and predictive values: foundations, pliabilities, and pitfalls in research and practice. Front Public Health. 2017;5:307. doi:10.3389/fpubh.2017.00307
   PubMed Web of Science ®Google Scholar
• Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10(3):227–245. doi:10.1007/s10461-006-9078-6
   PubMed Web of Science ®Google Scholar
• Nieuwkerk PT, Oort FJ. Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis. J Acquir Immune Defic Syndr. 2005;38(4):445–448. doi:10.1097/01.qai.0000147522.34369.12
   PubMed Web of Science ®Google Scholar
• Moore DM, Mermin J, Awor A, Yip B, Hogg RS, Montaner JS. Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr. 2006;43(4):436–439. doi:10.1097/01.qai.0000243105.80393.42
   PubMed Web of Science ®Google Scholar
• Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci. 1986;1:54–75.
   Google Scholar
• Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29–36. doi:10.1148/radiology.143.1.7063747
   PubMed Web of Science ®Google Scholar
• Efron B. Better bootstrap confidence intervals. J Am Stat Assoc. 1987;82(397):171–185. doi:10.1080/01621459.1987.10478410
   Web of Science ®Google Scholar
• Fullman N, Yearwood J, Abay SM, et al. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet. 2018;391(10136):2236–2271.
   PubMed Web of Science ®Google Scholar
• Dunbar-Jacob J, Rohay JM. Predictors of medication adherence: fact or artifact. J Behav Med. 2016;39(6):957–968. doi:10.1007/s10865-016-9752-8
   PubMed Web of Science ®Google Scholar
• Collaboration ATC. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003;362(9385):679–686. doi:10.1016/S0140-6736(03)14229-8
   PubMed Web of Science ®Google Scholar
• Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33(8):1417–1423. doi:10.1086/323201
   PubMed Web of Science ®Google Scholar
• Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283(15):2008–2012. doi:10.1001/jama.283.15.2008
   PubMed Web of Science ®Google Scholar
• Bisson G, Gross R, Gaolathe T, et al. Diagnostic characteristics of CD4 cell count response in predicting virologic response in HIV-infected patients initiating HAART in Botswana. Pharmacoepidemiol Drug Saf. 2006;15:S67–S68.
   Web of Science ®Google Scholar
• Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. Aids. 2004;18(6):887–895. doi:10.1097/00002030-200404090-00006
   PubMed Web of Science ®Google Scholar
• Initiative TMb, World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach; 2004.
   Google Scholar
• Curran J, Debas H, Arya M, Kelley P, Knobler S, Pray L. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a Public Health Approach; 2005.
   Google Scholar